Skip to content

Norfloxacin

FDA-approved product (tablet, oral), marketed as Chibroxin, Noroxin.

Registered studies
30
Lab records
179
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Norfloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA06; WHO ATC S01AE02

Repurposing investigation

Norfloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA93.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli98.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae92.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis74.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 45 of 47 lab records
  • E. coli: measured active in 51 of 52 lab records
  • K. pneumoniae: measured active in 65 of 80 lab records
Show the latest 150 of 179 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Norfloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)

    NCT06199843 · start 2024-01-05

    Registered record
    Registry ID
    NCT06199843
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Rifaximin; Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-01-05
    Completion
    2024-12-31
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionRifaximin; Norfloxacin
    PhaseNot applicable
    Registry statusUnknown
  • An Comparative Pharmacokinetic Study of Amlodipine Besylate Controlled-release Tablets,China in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions

    NCT05667818 · start 2023-01-28

    Registered record
    Registry ID
    NCT05667818
    Conditions
    Hypertension
    Interventions
    Amlodipine besylate tablets (trade name: Norfloxacin ®); Amlodipine besylate controlled-release tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2023-01-28
    Completion
    2023-03-10
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmlodipine besylate tablets (trade name: Norfloxacin ®); Amlodipine besylate controlled-release tablets
    PhasePhase 1
    Registry statusUnknown
  • Comparative Study of Secondary Prophylaxis for SBP

    NCT06827756 · start 2021-03-01

    Registered record
    Registry ID
    NCT06827756
    Conditions
    Spontaneous Bacterial Peritonitis; Cirrhoses, Liver; Ascites
    Interventions
    Norfloxacin 400 MG; Nitazoxanide 500 MG; Colistin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2022-02-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis; Cirrhoses, Liver; Ascites
    InterventionNorfloxacin 400 MG; Nitazoxanide 500 MG; Colistin
    PhasePhase 4
    Registry statusCompleted
  • Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

    NCT04746937 · start 2021-03

    Registered record
    Registry ID
    NCT04746937
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Nitazoxanide; Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-03
    Completion
    2022-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionNitazoxanide; Norfloxacin
    PhasePhase 3
    Registry statusUnknown
  • Midodrine and Albumin in Patients With Refractory Ascites

    NCT04621617 · start 2020-11

    Registered record
    Registry ID
    NCT04621617
    Conditions
    Refractory Ascites
    Interventions
    Albumin; Midodrine; Standard medical therapy (SMT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-11
    Completion
    2022-04
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Ascites
    InterventionAlbumin; Midodrine; Standard medical therapy (SMT)
    PhasePhase 3
    Registry statusUnknown
  • Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis

    NCT04159870 · start 2019-11-05

    Registered record
    Registry ID
    NCT04159870
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Rifaximin; Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-11-05
    Completion
    2021-12-20
    Enrolment
    322

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionRifaximin; Norfloxacin
    PhasePhase 3
    Registry statusUnknown
  • Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan

    NCT05106803 · start 2019-08-01

    Registered record
    Registry ID
    NCT05106803
    Conditions
    Bacterial Infections; Antibiotic Resistant Infection; Surgical Site Infection
    Interventions
    ciprofloxacin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-08-01
    Completion
    2019-10-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections; Antibiotic Resistant Infection; Surgical Site Infection
    Interventionciprofloxacin
    PhaseNot recorded
    Registry statusCompleted
  • Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

    NCT05621005 · start 2019-03-01

    Registered record
    Registry ID
    NCT05621005
    Conditions
    Ascites Infection
    Interventions
    Rifaximin 550 milligram Oral Tablet [XIFAXAN]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-03-01
    Completion
    2022-08-01
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAscites Infection
    InterventionRifaximin 550 milligram Oral Tablet [XIFAXAN]
    PhasePhase 2
    Registry statusCompleted
  • Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

    NCT04161768 · start 2018-12-01

    Registered record
    Registry ID
    NCT04161768
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Norfloxacin; Itopride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-12-01
    Completion
    2028-12-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionNorfloxacin; Itopride
    PhasePhase 3
    Registry statusRecruiting
  • Medication Adherence in Patients With Liver Cirrhosis

    NCT03627338 · start 2018-09-01

    Registered record
    Registry ID
    NCT03627338
    Conditions
    Medication Adherence
    Interventions
    questionaire, interview
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-09-01
    Completion
    2021-05-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedication Adherence
    Interventionquestionaire, interview
    PhaseNot recorded
    Registry statusUnknown
  • Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis

    NCT03702426 · start 2018-07-23

    Registered record
    Registry ID
    NCT03702426
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    GMCSF; Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-07-23
    Completion
    2019-07-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionGMCSF; Norfloxacin
    PhaseNot applicable
    Registry statusCompleted
  • Noroxin Efficacy and Safety Trial

    NCT03506256 · start 2018-05-10

    Registered record
    Registry ID
    NCT03506256
    Conditions
    Urinary Tract Infections
    Interventions
    Norfloxacin 400 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-05-10
    Completion
    2018-07-30
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionNorfloxacin 400 MG
    PhasePhase 4
    Registry statusUnknown
  • A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

    NCT03479736 · start 2017-11-20

    Registered record
    Registry ID
    NCT03479736
    Conditions
    Retinal Detachment; Achilles Tendon; Aneurysm, Dissecting
    Interventions
    Oral Fluoroquinolones (FQ); Other Antibiotics; Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-11-20
    Completion
    2018-06-04
    Enrolment
    117,911

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Detachment; Achilles Tendon; Aneurysm, Dissecting
    InterventionOral Fluoroquinolones (FQ); Other Antibiotics; Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
    PhaseNot recorded
    Registry statusCompleted
  • Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis

    NCT03695705 · start 2016-01-01

    Registered record
    Registry ID
    NCT03695705
    Conditions
    Cirrhosis, Liver
    Interventions
    Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-01
    Completion
    2017-06-30
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver
    InterventionRifaximin 550 mg twice a day and Norfloxacin 400 mg once a day
    PhasePhase 3
    Registry statusCompleted
  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated